Nano Farmakoloji ve Tek Sağlığa Giriş
Özet
Ortaya çıkan bulaşıcı hastalıklar, antibiyotik direnci ve çevresel bozulma gibi küresel sağlık sorunları oldukça karmaşık ve birbiriyle bağlantılı olgulardır. Bu zorlukların üstesinden gelmek, geleneksel disiplin sınırlarını aşan yenilikçi ve bütünleşik yaklaşımları gerektirmektedir. Tek Sağlık yaklaşımı, insan, hayvan ve ekosistemlerin sağlığının ayrılmaz bir şekilde bağlantılı olduğunu kabul eden birleştirici bir çerçeve olarak ortaya çıkmıştır. Bu yaklaşım, çeşitli sektörler ve disiplinler arasında iş birliğini teşvik ederek, çok yönlü sağlık tehditlerine karşı daha etkili ve sürdürülebilir çözümler geliştirmeyi amaçlamaktadır. Günümüzde bile insanlık için ciddi bir sorun teşkil eden HIV gibi hastalıkların yanı sıra çeşitli tipte ciddi ve karmaşık inflamatuar veya bulaşıcı hastalıklar yaşamı tehdit eder niteliktedir. Nanotıp, erken hastalık tespiti ve önlenmesi, daha iyi teşhis, etkili tedavi ve araştırmayı mümkün kılar. Eş zamanlı olarak, nanoteknolojinin farmakolojiye uygulanması olan nanofarmakoloji, ilaç dağıtımı, teşhis ve tedaviler için çığır açan çözümler sunmaktadır. Nanofarmakoloji, ilaç etkinliğini, güvenliğini ve hedefe yönelik etkisini artırma potansiyeli ile geleneksel farmakolojik yaklaşımların sınırlamalarının üstesinden gelme olanağı sunmaktadır. Bu bölümde küresel sağlık sorunlarının ele alınmasında Tek Sağlık yaklaşımı ile nanofarmakoloji arasındaki sinerjik ilişki ortaya konulacak; nanofarmakolojinin, insan, hayvan ve çevrenin birbiriyle bağlantılı sağlığını hedef alarak Tek Sağlık hedeflerine ulaşmada nasıl güçlü bir araç olabileceği vurgulanacaktır.
Global health challenges such as emerging infectious diseases, antibiotic resistance and environmental degradation are highly complex and interconnected phenomena. Addressing these challenges requires innovative and integrated approaches that cross traditional disciplinary boundaries. The One Health approach has emerged as a unifying framework that recognises that the health of humans, animals and ecosystems is inextricably linked. It aims to develop more effective and sustainable solutions to multifaceted health threats by fostering collaboration across various sectors and disciplines. Life-threatening diseases such as HIV, which still pose a serious challenge to humanity today, as well as various types of serious and complex inflammatory or infectious diseases. Nanomedicine enables early disease detection and prevention, better diagnosis, effective treatment and research. Simultaneously, nanopharmacology, the application of nanotechnology to pharmacology, offers breakthrough solutions for drug delivery, diagnostics and treatments. Nanopharmacology offers the opportunity to overcome the limitations of traditional pharmacological approaches with the potential to improve drug efficacy, safety and targeted action. This chapter will explore the synergistic relationship between the One Health approach and nanopharmacology in addressing global health challenges and highlight how nanopharmacology can be a powerful tool to achieve One Health goals by targeting the interconnected health of humans, animals and the environment.
Referanslar
Preston CJ. The synthetic age: Outdesigning evolution, resurrecting species, and reengineering our world, United States of America, MIT Press, 2019.
Kurtuluş D, Kuzukıran, Ö, Filazi, A. Mechanisms of antifungal action of nanomaterials. In: V. International Topkapı Congress, March, 19-21, 2025, İstanbul, Türkiye, Proceedings Book. ISBN: 979-8-89695-051-6, p.635-640.
Kshersagar J, Bohara RA, Joshi MG. Pharmacological study of hybrid nanostructures. In: Bohara RA, Thorat N. (eds). Hybrid nanostructures for cancer theranostics, United States of America: Elsevier; 2019. p. 87–104,
Martín Giménez VM, Kassuha DE, Manucha W. Nanomedicine applied to cardiovascular diseases: latest developments. Therapeutic Advance in Cardiovascular Disesase. 2017;11(4): 133–142. Doi: 10.1177/1753944717692
Charil A, Yousry TA, Rovaris M, et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation”. The Lancet Neurology. 2006;5(10):841–852. doi: 10.1016/S1474-4422(06)70572-5.
World Health Organization, UNEP United Nations Environment Programme, & World Organisation for Animal Health. One health joint plan of action (2022‒2026): working together for the health of humans, animals, plants and the environment. (26/04/2025 tarihinde https://www.woah.org/app/uploads/2024/04/en-one-health-policy-brief-.pdf adresinden ulaşılmıştır.
Centers for Disease Control and Prevention. About One Health - CDC, (24/04/2025 tarihinde https://www.cdc.gov/one-health/about/index.html adresinden ulaşılmıştır)
Hauck TS, Giri S, Gao, Y, et al. Nanotechnology diagnostics for infectious diseases prevalent in developing countries. Advanced Drug Delivery Reviews. 2010;62(4-5): 438–448. Doi:10.1016/j.addr.2009.11.015
Reddy SJ. The recent advances in the nanotechnology and its applications-A review. IOSR Journal of Biotechnology and Biochemistry. 2020;6(1):24-30. doı: 10.9790/264X-0601012430
Quintanar‐Guerrero D, Leyva‐Gómez G, Vergara NEM, et al., Nanopharmaceuticals. In: Visakh PM (ed). Nanomaterials and Nanotechnology in Medicine, John Wiley & Sons Ltd. 2023. p.87-114.
Pitt SJ, Gunn A. The one health concept. British Journal of Biomedical Science, 2024;81: 12366. Doi: 10.3389/bjbs.2024.12366
Adisasmito WB, Almuhairi S, Behravesh CB, et al. One Health: A new definition for a sustainable and healthy future. PLoS pathogens, 2022;18(6): e1010537. Doi:10.1371/journal.ppat.1010537
Kurtuluş D, Kuzukıran Ö, Filazi A. Nanotechnological Methods Used in the Preparation of Antifungals. In: V. International Topkapı Congress, March, 19-21, 2025, İstanbul. Proceedings Book. ISBN: 979-8-89695-051-6, p.155-161.
Vignesh BE, Tamil SA. Nanopharmacology: A novel approach in therapeutics. Asian Journal of Research in Pharmaceutical Science, 2019; 9(1): 9-16. Doi:10.5958/2231-5659.2019.00003.1
Sulochana G, Rajeshkumar S, Natarajan PM. Nanopharmacology and Pharmacotherapeutics. In: Chokkareddy R, Kanchi S, Redhi GG (eds) Sustainable Nanomaterials for Treatment and Diagnosis of Infectious Diseases, Scrivener Publishing LLC; 2025. p. 81-112.
Emeihe EV, Nwankwo EI, Ajegbile MD, et al. Revolutionizing drug delivery systems: Nanotechnology-based approaches for targeted therapy. International Journal of Life Science Research Archive, 2024; 7(1): 040-058. Doi:10.53771/ijlsra.2024.7.1.0060
Srivastava P, Kumari BM, Rajeswari SU, et al. A Comprehensive Review of Advancements in Pharmacology and Drug Discovery. Journal of Experimental Zoology India, 2024; 27(2). 2005. 10.51470/jez.2024.27.2.2005
Kobayashi RKT, Dhakal S, Nakazato G. Editorial: The Use of Nanoparticles in the Diagnosis and Therapy of Infectious Disease in Animals. Frontiers in Veterinary Science. 2022; 8: 829540. Doi: 10.3389/fvets.2021.829540.
Rios TB, Maximiano MR, Feitosa GC, et al. Nanosensors for animal infectious disease detection. Sensing and Bio-Sensing Research, 2024;43:100622. Doi:10.1016/j.sbsr.2024.100622
Hassan AA, Sayed-ElAhl RM, El Hamaky AM, et al. (2022). Nanodiagnostics: New Tools for Detection of Animal Pathogens. In: Lim K-T, Abd-Elsalam KA (eds). Nanorobotics and Nanodiagnostics in Integrative Biology and Biomedicine. Springer International Publishing, 2023. p. 299-325.
Bhardwaj V, Kaushik A, Khatib ZM, et al. Recalcitrant issues and new frontiers in nano-pharmacology. Frontiers in pharmacology, 2019; 10, 1369. Doi:10.3389/fphar.2019.01369
Angelou A, Pappa A, Markov PV, et al. Early warning system of the seasonal west nile virus infection risk in humans in northern greece, 2020–2024. Scientific Reports, 2025;15(1):7129. Doi:10.1038/s41598-025-91996-9
Liew KB, Koh EV, Kong XE, et al. Recent Advancements in Nanopharmaceuticals for Novel Drug Delivery Systems. Pharmaceutical Nanotechnology, 2025; 13(2), 271-286. Doi:10.2174/0122117385324246240826042254
Sarella PNK, Vipparthi AK, Valluri S, et al. Nanorobotics: Pioneering drug delivery and development in pharmaceuticals. 2024; 16 (1), 81-90. DOI: 10.52711/0975-4377.2024.00014
Nguyen NN, Nguyen NT, Nguyen PT, et al. Current and emerging nanotechnology for sustainable development of agriculture: Implementation design strategy and application. Heliyon, 2024; 10(10), e31503. Doi: 10.1016/j.heliyon.2024.e31503
Shan X, Gong X, Li J, et al. Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharmaceutica Sinica B, 2022; 12(7), 3028-3048. Doi:10.1016/j.apsb.2022.02.025
Hua S, de Matos MBC, Metselaar JM, et al. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Frontiers in Pharmacology, 2018; 9 (790), 14. doi: 10.3389/fphar.2018.00790
Barenholz Y. DOXIL - The first FDA-approved nano-drug: lessons learned. Journal of Controlled Release, 2012; 160(2):117–134. doi: 10.1016/j.jconrel.2012.03.020
World Health Organization. Cancer. (26/04/2025 tarihinde https://www.WHO.int/news-room/fact-sheets/detail/cancer adresinden ulaşılmıştır)
The Business Research Company Nanaopharmaceuticals Global Market Market Report (23/04/2025 tarihinde https://www.thebusinessresearchcompany.com/report/nanopharmaceuti cals-global-market-report adresinden ulaşılmıştır)
Hwang TJ, Carpenter D, Lauffenburger JC, et al. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Internal Medicine. 2016; 176 (12), 1826–1833. doi: 10.1001/jamainternmed.2016.6008
Ajaz M, Rasool W, Mahmood A. Comprehensive Review of Nanotechnology: Innovations and Multidisciplinary Applications: Comprehensive Review of Nanotechnology. Futuristic Biotechnology, 2024; 12-18. Doi:10.54393/fbt.v4i01.81
Elhenawy S, Khraisheh M, AlMomani F, et al. Emerging nanomaterials for drinking water purification: A new era of water treatment technology. Nanomaterials, 2024; 14(21), 1707. doi: 10.3390/nano14211707.
Pathiraja G. Advances in nanotechnology for the removal and detection of emerging contaminants from water. Frontiers in Chemistry, 2025; 13, 1540487. Doi:10.3389/fchem.2025.1540487
Muhammad P, Zada A, Rashid J, et al. Defect engineering in nanocatalysts: From design and synthesis to applications. Advanced Functional Materials, 2024; 34(29):2314686. Doi:10.1002/adfm.202314686
Gong W, Bai L, Liang H. Membrane-based technologies for removing emerging contaminants in urban water systems: Limitations, successes, and future improvements. Desalination, 2024; 590, 117974. Doi:10.1016/j.desal.2024.117974
Liu X, Sathishkumar K, Zhang H, et al. Frontiers in environmental cleanup: Recent advances in remediation of emerging pollutants from soil and water. Journal of Hazardous Materials Advances, 2024; 100461. Doi:10.1016/j.hazadv.2024.100461
World Health Organization (2017). One Health (24/04/2025 tarihinde https://www.WHO.int/news-room/questions-and-answers/item/one-health adresinden ulaşılmıştır)
Parvin N, Joo SW, Mandal TK. Nanomaterial-based strategies to combat antibiotic resistance: Mechanisms and applications. Antibiotics, 2025; 14(2), 207. Doi: 10.3390/antibiotics14020207
Vijayakumar S, Divya M, Vaseeharan B, et al. Biogenic preparation and characterization of ZnO nanoparticles from natural polysaccharide Azadirachta indica. L.(neem gum) and its clinical implications. Journal of Cluster Science, 2021; 32, 983-993. Doi:10.1007/s10876-020-01863-y
Jarockyte G, Karabanovas V, Rotomskis R, et al. Multiplexed nanobiosensors: current trends in early diagnostics. Sensors, 2020; 20(23), 6890.doi:10.3390/s20236890
Dhand C, Dwivedi N, Loh XJ, et al. Methods and strategies for the synthesis of diverse nanoparticles and their applications: a comprehensive overview. RSC Advances, 2015; 5, 127, 105003–105037, 2015. Doi: 10.1039/C5RA19388E
Malik S, Muhammad K, Waheed Y. Emerging applications of nanotechnology in healthcare and medicine. Molecules, 2023; 28(18), 6624. Doi:10.3390/molecules28186624
Akhtar A. The flaws and human harms of animal experimentation. Cambridge Quality Healthcare Ethics. 2015; 24 (4), 407–419. doi: 10.1017/S0963180115000079
Burgdorf T, Persma AH, Landsiedel R, et al. Workshop on the validation and regulatory acceptance of innovative 3R approaches in regulatory toxicology - Evolution versus revolution. In Vitro Toxicology. 2019; 59, 1–11. doi: 10.1016/j.tiv.2019.03.039
Sanhai WR, Sakamoto JH, Canady R, et al. Seven challenges for nanomedicine. Nature Nanotechnology. 2008; 3, 242–244. doi: 10.1038/nnano.2008.114
Frangioni JV. New technologies for human cancer imaging. Journal of Clinical Oncology, 2008; 26 (24), 4012–4021. doi: 10.1200/JCO.2007.14.3065
Leff DR, Warren OJ, Enfield LC, et al. Diffuse optical imaging of the healthy and diseased breast: a systematic review. Breast Cancer Research and Treatment. 2008; 108, 9–22. doi: 10.1007/s10549-007-9582-z
Godavarty A, Rodriguez S, Jung YJ, et al. Optical imaging for breast cancer prescreening. Breast Cancer: Targets and Therapy. 2015; 7, 193–209. doi: 10.2147/BCTT.S51702
Desroches J, Jermyn M, Pinto M, et al. A new method using Raman spectroscopy for in vivo targeted brain cancer tissue biopsy. Scientific Reports. 2018; 1792 (8), 10. doi: 10.1038/s41598-018-20233-3
Srinivasan S, Bhardwaj V, Nagasetti A, et al. Multifunctional surface-enhanced Raman spectroscopy-detectable silver nanoparticles for combined photodynamic therapy and pH-triggered chemotherapy. Journal of Biomedicine and Nanotechnology. 2016; 12912: 2202–2219. doi: 10.1166/jbn.2016.2312.
Zhang K, Hao C, Huo Y, et al. Labelfree diagnosis of lung cancer with tissue-slice surface-enhanced Raman spectroscopy and statistical analysis. Lasers in Medical Science. 2019; 1–7. doi: 10.1007/s10103-019-02781-w
Kluza E, Strijkers GJ, Nicolay K. (2012). Multifunctional magnetic resonance imaging probes. In: Schober O, Riemann B. Molecular imaging in oncology. Springer Nature, 2013. P.151–190.
Langereis S, Geelen T, Grull H, et al. Paramagnetic liposomes for molecular MRI and MRI-guided drug delivery. NMR Biomedicine. 2013; 26 (7), 728–744. doi: 10.1002/nbm.2971
Bolan PJ, Kim E, Herman BA, et al. Magnetic Resonance Spectroscopy of breast cancer for assessing early treatment response; results from the ACRIN 6657 MRS trial. Jornal of Magnetic Resonance Imaging. 2017; 46 (1), 290–302. doi: 10.1002/jmri.25560
Kircher MF, Zerda A, Jokerst JV, et al. A brain tumor molecular imaging strategy using a new triplemodality MRI-Photoacoustic-Raman nanoparticle. Nature Medicine. 2012; 18 (5), 829–835. doi: 10.1038/nm.2721
Shen T, Zhang Y, Kirillov AM, et al. Two photon sensitized hollow Gd2O3:Eu3+ nanocomposites for real-time dualmode imaging and monitoring of anti-cancer drug release. Chemical Communications. 2016; 52 (7), 1447–1450. doi: 10.1039/C5CC07609A
Schork NJ. Time for one-person trials. Nature. 2015; 520, 609–611. Doi 0.1038/520609a
Chokkareddy R, Kanchi S., Redhi GG. Sustainable Nanomaterials for Treatment and Diagnosis of Infectious Diseases, Scrivener Publishing LLC, 2025.
Rosenblum D, Joshi N, Tao W, et al. Progress and challenges towards targeted delivery of cancer therapeutics. Nature Communications. 2018; 9 (1410), 12. doi: 10.1038/s41467-018-03705-y
Masserini M. Nanoparticles for brain drug delivery. International Scholarly Research Notices. 2013; (238428), 18. doi: 10.1155/2013/238428
Jakoby J, Beuschlein F, Mentz S, et al. Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects. Oncotarget 2015; 6 (41), 43698–43711. doi: 10.18632/oncotarget.6191
Bennett NK., Chmielowski R, Abdelhamid DS, et al. Polymer brain-nanotherapeutics for multipronged inhibition of microglial alpha-synuclein aggregation, activation, and neurotoxicity. Biomaterials, 2016; 111, 179–189. doi: 10.1016/j.biomaterials.2016.10.001
Gray MD, Lyon PC, Mannaris C, et al. Focused ultrasound hyperthermia for targeted drug release from thermosensitive liposomes: results phase I trial. Radiology. 2019; 291, 232–238. doi: 10.1148/radiol.2018181445
Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. Journal of Neuro-Oncology. 2011; 103 (2), 317–324. doi: 10.1007/s11060-010-0389-0
Kaushik A, Jayant RD, Moshaie RN, et al. Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers. Scientific Reports. 2016; 6 (25309), 10. doi:10.1038/srep25309
Rodzinski A, Guduru R, Liang P, et al. Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles. Scientific Reports. 2016; 6 (20867), 14. doi: 10.1038/srep20867
Nair M, Guduru R, Liang P, et al. Externally controlled on-demand release of anti-HIV drug using magnetoelectric nanoparticles as carriers. Nature Communications. 2013; 4 (1707), 8. doi: 10.1038/ncomms3729
Stimphil E, Nagesetti A, Guduru R, et al. Physics considerations in targeted anti-cancer drug delivery by magnetoelectric nanoparticles. Applied Physics Reviews. 2017; 4 (2), 9. doi: 10.1063/1.4978642
Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Internal Medicine. 2017; 177 (11), 1569–1575. doi: 10.1001/jamainternmed.2017.3601
Bawa R, Audette GF, Reese BE. Handbook of clinical nanomedicine: law, business, regulation, safety, and risk. Boca Raton, CRC Press, Taylor and Francis Group, 2016.
Food and Drug Administration. (2014). Considering whether an FDA regulated product involves the application of nanotechnology, Docket# FDA-2010-D-0530. (26/04/2025 tarihinde https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considering-whether-fda-regulated-product-involves-application-nanotechnology adresinden ulaşılmıştır)
European Medicines Agency. (2013) Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. (EMA/CHMP/SWP/100094/2011) (26/04/2025 tarihinde https://etp-nanomedicine.eu/wp-content/uploads/2018/10/reflection-paper-data-requirements-intravenous-liposomal-products-developed-reference-innovator_en-0.pdf adresinden ulaşılmıştır).
Mamidi RNVS, Weng S, Stellar S, et al. Pharmacokinetics, efficacy, and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products? Cancer Chemotherapy and Pharmacology. 2010; 6696, 1173–1184. doi: 10.1007/s00280-010-1406-x
